Dr. Gearóid Tuohy

GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France

GenSight Biologics (Euronext: SIGHT), announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament… Read More »GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France